Paula J. Anderson

TL;DR: None of the pooled metaanalyses showed a significant difference between devices in any efficacy outcome in any patient group for each of the clinical settings that was investigated.

TL;DR: The data showed that deposition of these ultrafine particles was increased in subjects with obstructive lung disease when compared with normal subjects, while it was unchanged in Subjects with restrictive lung disease.

TL;DR: Inhaled therapies have been used since ancient times and may have had their origins with the smoking of datura preparations in India 4,000 years ago, but are now in an era of rapid technologic progress in inhaled drug delivery and applications of aerosol science, with the use of the aerosolized route for drugs for systemic therapy and for gene replacement therapy.

TL;DR: Respimat is a novel, multidose, propellant-free, hand-held, liquid inhaler that represents a new category of inhaler devices and was preferred over the pMDI by patients with COPD and other obstructive lung diseases.

TL;DR: Denufosol improved lung function relative to placebo in cystic fibrosis patients with normal to mildly impaired lung function and was well tolerated with adverse event and growth profiles similar to placebo.